223 related articles for article (PubMed ID: 28109618)
1. Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients-A longitudinal analysis.
Wunderlich C; Oliviera I; Figueiredo CP; Rech J; Schett G
Semin Arthritis Rheum; 2017 Jun; 46(6):709-714. PubMed ID: 28109618
[TBL] [Abstract][Full Text] [Related]
2. Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study.
Harrold LR; Litman HJ; Connolly SE; Kelly S; Hua W; Alemao E; Rosenblatt L; Rebello S; Kremer JM
J Rheumatol; 2018 Jan; 45(1):32-39. PubMed ID: 29093151
[TBL] [Abstract][Full Text] [Related]
3. EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.
Gülfe A; Wallman JK; Kristensen LE
Arthritis Res Ther; 2016 Feb; 18():51. PubMed ID: 26892115
[TBL] [Abstract][Full Text] [Related]
4. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.
Strangfeld A; Richter A; Siegmund B; Herzer P; Rockwitz K; Demary W; Aringer M; Meißner Y; Zink A; Listing J
Ann Rheum Dis; 2017 Mar; 76(3):504-510. PubMed ID: 27405509
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry.
Harrold LR; Reed GW; Solomon DH; Curtis JR; Liu M; Greenberg JD; Kremer JM
Arthritis Res Ther; 2016 Dec; 18(1):280. PubMed ID: 27906048
[TBL] [Abstract][Full Text] [Related]
6. Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis.
Walker UA; Jaeger VK; Chatzidionysiou K; Hetland ML; Hauge EM; Pavelka K; Nordström DC; Canhão H; Tomšič M; van Vollenhoven R; Gabay C
Rheumatology (Oxford); 2016 Feb; 55(2):230-6. PubMed ID: 26316581
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry.
Monti S; Klersy C; Gorla R; Sarzi-Puttini P; Atzeni F; Pellerito R; Fusaro E; Paolazzi G; Rocchetta PA; Favalli EG; Marchesoni A; Caporali R
Clin Rheumatol; 2017 Apr; 36(4):753-761. PubMed ID: 28058538
[TBL] [Abstract][Full Text] [Related]
8. Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice.
Backhaus M; Kaufmann J; Richter C; Wassenberg S; Roske AE; Hellmann P; Gaubitz M
Clin Rheumatol; 2015 Apr; 34(4):673-81. PubMed ID: 25630309
[TBL] [Abstract][Full Text] [Related]
9. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
10. Abatacept induced long-term non-progressive reduction in gamma-globulins and autoantibodies: dissociation from disease activity control.
Dinis VG; Viana VT; Leon EP; Silva CA; Saad CG; Moraes JC; Bonfa ES; Medeiros-Ribeiro AC
Clin Rheumatol; 2020 Jun; 39(6):1747-1755. PubMed ID: 31927715
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
Akiyama M; Kaneko Y; Kondo H; Takeuchi T
Clin Rheumatol; 2016 Nov; 35(11):2829-2834. PubMed ID: 26971256
[TBL] [Abstract][Full Text] [Related]
12. Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status.
Boeters DM; Burgers LE; Toes RE; van der Helm-van Mil A
Ann Rheum Dis; 2019 Nov; 78(11):1497-1504. PubMed ID: 31413004
[TBL] [Abstract][Full Text] [Related]
13. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial.
Sokolove J; Schiff M; Fleischmann R; Weinblatt ME; Connolly SE; Johnsen A; Zhu J; Maldonado MA; Patel S; Robinson WH
Ann Rheum Dis; 2016 Apr; 75(4):709-14. PubMed ID: 26359449
[TBL] [Abstract][Full Text] [Related]
14. Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry.
Sebastiani M; Venerito V; Bugatti S; Bazzani C; Biggioggero M; Petricca L; Foti R; Bortoluzzi A; Balduzzi S; Visalli E; Frediani B; Manfredi A; Gremese E; Favalli E; Iannone F; Ferraccioli G; Lapadula G;
Clin Rheumatol; 2021 Oct; 40(10):4039-4047. PubMed ID: 33881676
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab and rituximab have similar effectiveness and are both superior to a second tumour necrosis factor inhibitor in rheumatoid arthritis patients who discontinued a first TNF inhibitor.
Santos-Faria D; Tavares-Costa J; Eusébio M; Leite Silva J; Ramos Rodrigues J; Sousa-Neves J; Duarte AC; Lopes C; Valido A; Dinis J; Freitas J; Santiago M; Ferreira R; Ganhão S; Miranda L; Peixoto D; Teixeira F; Alcino S; Afonso C; Santos MJ
Acta Reumatol Port; 2019; 44(2):103-113. PubMed ID: 31243259
[TBL] [Abstract][Full Text] [Related]
16. Association Between Baseline Anti-cyclic Citrullinated Peptide Antibodies and 6-Month Clinical Response Following Abatacept or TNF Inhibitor Treatment: A Real-World Analysis of Biologic-Experienced Patients with RA.
Harrold LR; Bryson J; Lehman T; Zhuo J; Gao S; Han X; Schrader A; Rebello S; Pappas DA; Sommers T; Kremer JM
Rheumatol Ther; 2021 Jun; 8(2):937-953. PubMed ID: 34047953
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing the choice of biologic therapy following Rituximab in patients with rheumatoid arthritis: A retrospective study using propensity score.
Vial G; De Pouilly A; Scouppe L; Pereira B; Daien C; Lukas C; Ruyssen-Witrand A; Vergne-Salle P; Richez C; Tournadre A
Joint Bone Spine; 2020 Jan; 87(1):43-48. PubMed ID: 31369868
[TBL] [Abstract][Full Text] [Related]
18. Effect of rituximab or tumour necrosis factor inhibitors on lung infection and survival in rheumatoid arthritis-associated bronchiectasis.
Md Yusof MY; Iqbal K; Darby M; Lettieri G; Vital EM; Beirne P; Dass S; Emery P; Kelly C
Rheumatology (Oxford); 2020 Oct; 59(10):2838-2846. PubMed ID: 32065634
[TBL] [Abstract][Full Text] [Related]
19. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab.
Provan SA; Berg IJ; Hammer HB; Mathiessen A; Kvien TK; Semb AG
PLoS One; 2015; 10(6):e0130709. PubMed ID: 26114946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
